[1]
D'souza RS, Levandowski C, Slavov D, Graw SL, Allen LA, Adler E, Mestroni L, Taylor MR. Danon disease: clinical features, evaluation, and management. Circulation. Heart failure. 2014 Sep:7(5):843-9. doi: 10.1161/CIRCHEARTFAILURE.114.001105. Epub
[PubMed PMID: 25228319]
[2]
Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, Mora M, Riggs JE, Oh SJ, Koga Y, Sue CM, Yamamoto A, Murakami N, Shanske S, Byrne E, Bonilla E, Nonaka I, DiMauro S, Hirano M. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000 Aug 24:406(6798):906-10
[PubMed PMID: 10972294]
[4]
Charron P, Villard E, Sébillon P, Laforêt P, Maisonobe T, Duboscq-Bidot L, Romero N, Drouin-Garraud V, Frébourg T, Richard P, Eymard B, Komajda M. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart (British Cardiac Society). 2004 Aug:90(8):842-6
[PubMed PMID: 15253947]
Level 3 (low-level) evidence
[5]
Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, Spirito P, Wright GB, Kanter RJ, Seidman CE, Seidman JG. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. The New England journal of medicine. 2005 Jan 27:352(4):362-72
[PubMed PMID: 15673802]
[7]
Konecki DS, Foetisch K, Zimmer KP, Schlotter M, Lichter-Konecki U. An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Biochemical and biophysical research communications. 1995 Oct 13:215(2):757-67
[PubMed PMID: 7488019]
[8]
Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genetics in medicine : official journal of the American College of Medical Genetics. 2011 Jun:13(6):563-8. doi: 10.1097/GIM.0b013e31820ad795. Epub
[PubMed PMID: 21415759]
[9]
Schorderet DF, Cottet S, Lobrinus JA, Borruat FX, Balmer A, Munier FL. Retinopathy in Danon disease. Archives of ophthalmology (Chicago, Ill. : 1960). 2007 Feb:125(2):231-6
[PubMed PMID: 17296900]
[10]
Yardeni M, Weisman O, Mandel H, Weinberger R, Quarta G, Salazar-Mendiguchía J, Garcia-Pavia P, Lobato-Rodríguez MJ, Simon LF, Dov F, Arad M, Gothelf D. Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation). American journal of medical genetics. Part A. 2017 Sep:173(9):2461-2466. doi: 10.1002/ajmg.a.38320. Epub 2017 Jun 19
[PubMed PMID: 28627787]
[11]
Balmer C, Ballhausen D, Bosshard NU, Steinmann B, Boltshauser E, Bauersfeld U, Superti-Furga A. Familial X-linked cardiomyopathy (Danon disease): diagnostic confirmation by mutation analysis of the LAMP2gene. European journal of pediatrics. 2005 Aug:164(8):509-14
[PubMed PMID: 15889279]
[12]
Sugie K, Yamamoto A, Murayama K, Oh SJ, Takahashi M, Mora M, Riggs JE, Colomer J, Iturriaga C, Meloni A, Lamperti C, Saitoh S, Byrne E, DiMauro S, Nonaka I, Hirano M, Nishino I. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002 Jun 25:58(12):1773-8
[PubMed PMID: 12084876]
[13]
Miani D, Taylor M, Mestroni L, D'Aurizio F, Finato N, Fanin M, Brigido S, Proclemer A. Sudden death associated with danon disease in women. The American journal of cardiology. 2012 Feb 1:109(3):406-11. doi: 10.1016/j.amjcard.2011.09.024. Epub 2011 Nov 9
[PubMed PMID: 22074992]
[14]
Prall FR, Drack A, Taylor M, Ku L, Olson JL, Gregory D, Mestroni L, Mandava N. Ophthalmic manifestations of Danon disease. Ophthalmology. 2006 Jun:113(6):1010-3
[PubMed PMID: 16751040]
[15]
Yang Z, Funke BH, Cripe LH, Vick GW 3rd, Mancini-Dinardo D, Peña LS, Kanter RJ, Wong B, Westerfield BH, Varela JJ, Fan Y, Towbin JA, Vatta M. LAMP2 microdeletions in patients with Danon disease. Circulation. Cardiovascular genetics. 2010 Apr:3(2):129-37. doi: 10.1161/CIRCGENETICS.109.901785. Epub 2010 Feb 20
[PubMed PMID: 20173215]
[16]
Posada C, García-Cruz A, García-Doval I, Millán BS, Teijeira S. Chloroquine-induced myopathy. Lupus. 2011 Jun:20(7):773-4. doi: 10.1177/0961203310385553. Epub 2011 Feb 7
[PubMed PMID: 21300683]
[17]
Sugie K, Komaki H, Eura N, Shiota T, Onoue K, Tsukaguchi H, Minami N, Ogawa M, Kiriyama T, Kataoka H, Saito Y, Nonaka I, Nishino I. A Nationwide Survey on Danon Disease in Japan. International journal of molecular sciences. 2018 Nov 8:19(11):. doi: 10.3390/ijms19113507. Epub 2018 Nov 8
[PubMed PMID: 30413001]
Level 3 (low-level) evidence
[18]
Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB, Almquist AK, Baffa JM, Saul JP, Ho CY, Seidman J, Seidman CE. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009 Mar 25:301(12):1253-9. doi: 10.1001/jama.2009.371. Epub
[PubMed PMID: 19318653]
Level 2 (mid-level) evidence
[19]
Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. Journal of cardiac failure. 2018 May:24(5):281-302. doi: 10.1016/j.cardfail.2018.03.004. Epub 2018 Mar 19
[PubMed PMID: 29567486]
Level 1 (high-level) evidence
[20]
D'souza RS, Mestroni L, Taylor MRG. Danon disease for the cardiologist: case report and review of the literature. Journal of community hospital internal medicine perspectives. 2017 Mar:7(2):107-114. doi: 10.1080/20009666.2017.1324239. Epub 2017 Jun 6
[PubMed PMID: 28638575]
Level 3 (low-level) evidence